Treatment of estrogen deficiency symptoms in women surviving breast cancer: Part 2: Hormone replacement therapy and breast cancer

ONCOLOGY

Volumn 13, Issue 2, 1999, Pages 245-267

  Swain, Sandra ^a   Santen, Richard ^b   Burger, Henry ^c   Pritchard, Kathleen ^d  

^a Comprehensive Breast Center ^*  (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLLITROPIN; GESTAGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE; PHYTOESTROGEN; PROGESTERONE; PROGESTERONE RECEPTOR; RISEDRONIC ACID; TAMOXIFEN CITRATE; TIBOLONE;

ADJUVANT THERAPY; BREAST CANCER; CANCER PALLIATIVE THERAPY; CONFERENCE PAPER; DRUG INDICATION; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HIGH RISK PATIENT; HUMAN; RECURRENCE RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN DISEASES; PROGESTERONE; PROGNOSIS; RISK FACTORS;

EID: 0032995149     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gambrell RD: Proposal to decrease the risk and improve the prognosis of breast cancer. Am J Obstet Gynecol 150:119-132, 1984.
2. Harding C, Knox WF, Faragher EB, et al: Hormone replacement therapy and tumour grade in breast cancer: A prospective study in a screening unit. Br Med J 312:1646-1647, 1996.
3. Bonnier P, Romain S, Giacalone PL, et al: Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85:1-17, 1995.
4. Gwyn K, Hao Y, Miller A, et al: The clinico-pathologic presentation of breast cancer in postmenopausal women exposed to hormone replacement therapy (abstract). Proc Am Soc Clin Oncol 16:133a, 1997.
5. Clark RM, Chua T: Breast cancer and pregnancy: The ultimate challenge. Clin Oncol (R Coll Radiol) 1:11-18, 1989.
6. Vassilopoulou-Sellin R, Zolinski C: Estrogen replacement therapy in women with breast cancer: a survey of patient attitudes. Am J Med Sci 304:145-149, 1992.
7. Dhodapkar MV, Ingle JN, Ahmann DL: Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 75:43-46, 1995.
8. Powles TJ, Hickish T, Casey S: Hormone replacement after breast cancer. Lancer 342:60-61, 1993.
9. Stoll BA: Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 25:1909-1913, 1995.
10. Disaia PJ: Estrogen replacement therapy for the breast cancer survivor: A reappraisal. J Surg Oncol 64:175-80, 1997.
11. Eden JA: A case controlled study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 2:67-72, 1995.
12. Loprinzi CL, Michalak JC, Quella SK, et al: Megestrol acetate for the prevention of hot flashes. N Engl J Med 331:347-352, 1994.
13. Cobleigh MA, Berris RF, Bush T, et al: Estrogen replacement therapy in breast cancer survivors: A time for change. JAMA 272:540-545, 1994.
14. Decker D, Cox T, Burdakin J, et al: Hormone replacement therapy (HRT) in breast cancer survivors (abstract). Proc Am Soc Clin Oncol 15:209, 1996.
15. Bluming AZ, Waisman JR, Dosik GA, et al: Hormone replacement therapy (HRT) in women with previously treated primary breast cancer, update IV (abstract). Proc Am Soc Clin Oncol 17:496, 1997.
16. Prior JC, Vigna YM, Wark JD, et al: Premenopausal ovariectomy-related bone loss: A randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 12:1851-1863, 1997.
17. Lippman M, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone responsive breast cancer in long-term tissue culture. Cancer Res 36:4595-4601, 1976.
18. Fuqua SAW: Estrogen and progesterone receptors and breast cancer, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast, pp 262-263. Philadelphia, Lippincott-Raven, 1996.
19. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332(24): 1589-1593, 1995.
20. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996.
21. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059, 1997.
22. Shairer C, Byrne C, Keyl PM, et al: Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer. Cancer Causes Control 5:491-500, 1994.
23. Ettinger B, Friedman GD, Bush T, et al: Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87(1):6-12, 1996.
24. Grodstein F, Stampfer MJ, Mansen JE, et al: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335(7):453-461, 1996.
25. Grady D, Rubin SM, Petitti DB, et al: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016-1037, 1992.
26. Calle EE, Miracle-McMahill HL, Thun MJ: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 87:517-523, 1995.
27. Col NF, Eckman MH, Karas RH, et al: Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 277:1140-1147, 1997.
28. Ragaz J, Coldman A: Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 16:2018-2024, 1998.